BioPharmX Announces Patent Award, Expanding Protection for Innovations in Solid Dosage Forms


New patent protects improvements in oral drug delivery

MENLO PARK, Calif., Aug. 9, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that the U.S. Patent and Trademark Office has granted a fifth patent to the company - which means that three of its drug delivery systems now have patent protection.

The patent, (U.S. Patent No. 10,034,899), entitled "Solid oral dosage form for breast symptoms," protects improvements in BioPharmX's novel system for the delivery of molecular iodine to treat fibrocystic breast condition. It recognizes the unique benefits provided by the addition of vitamins A and/or D and calcium and/or iron to the company's Violet® iodine, a novel and proprietary formulation for the treatment of fibrocystic breast condition, containing iodide and iodate salts that react to form molecular iodine when they are exposed to gastric pH.

This is the third patent granted to BioPharmX this year. The first, granted in February, was for the company's microencapsulation delivery system. The second, granted in March, protects the company's HyantX™ delivery system, which forms the basis for two investigational drugs, BPX-01* for acne and BPX-04* for rosacea.The company has another 31 patent applications pending, to protect all four of the BioPharmX delivery systems.

"The patents granted to us by the USPTO validate the novelty of our delivery systems," said R. Kehl Sink, PhD, Senior VP of Intellectual Property and Legal at BioPharmX. "These patents and the 31 pending patent applications protect our investment in product innovation for years to come."

Violet®, BioPharmX's first product, demonstrated that the company could overcome barriers that have historically stumped other pharmaceutical companies. This patent grant is another milestone in BioPharmX's record of innovation.

About BioPharmX Corporation
BioPharmX Corporation (NYSE American: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit

Forward-Looking Statements
This press release contains forward-looking statements related to the company's plans or developments that involve risks, uncertainties and assumptions, and are subject to the "safe harbor" of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "plan," "expect," "believe," "intend," "should," "may" or similar expressions. Important factors that could cause actual results to differ materially than those expressed or implied in such statements include, but are not limited to, the effect Violet may have for the treatment of fibrocystic breast condition, the likelihood of being granted additional patents, the company's ability to obtain and enforce patent and other intellectual property rights and changes in patent law in the United States and internationally. Additional risks are set forth in the company's filings with the Securities and Exchange Commission, including those described in the company's Quarterly Report on Form 10-Q for the most recent fiscal quarter. The forward-looking statements included in this news release are made only as of the date hereof, and the company undertakes no obligation to publicly update such statements.BioPharmX is a registered trademark of BioPharmX, Inc.

* Caution: BPX-01 and BPX-04 are new drugs limited by U.S. law to investigational use.


View original content with multimedia:

SOURCE BioPharmX Corporation

Company Codes: AMEX:BPMX

Back to news